Jazz Pharmaceuticals shared a post on LinkedIn:
“The science behind targeted therapies is continuing to advance, and so is our commitment behind it. Chumi Khurana, Senior Vice President and Oncology Franchise Head, discusses how the evolution toward precision is creating new possibilities in some of the most difficult-to-treat cancers.
Read how we are deepening our expertise in rare cancers where unmet need remains high and rigorous science has the potential to make a real difference for patients.”
Other articles about Jazz Pharmaceuticals on OncoDaily.